ONCOLOGY Vol 34 Issue 3

This review article discusses the concepts of a tumor microenvironment and a gut microbiome and their effects on responses to checkpoint inhibitors (CPIs). It also reviews recent research investigating these 3 topics, and how it can be applied to using CPIs in prostate cancer.

PARP inhibitors take center stage at the Society of Gynecologic Oncology’s 25th Annual Winter Meeting

ONCOLOGY recently sat down with Kenneth C. Anderson, MD, to discuss the current trends in multiple myeloma treatment, and the explosion of novel therapies that are paving the way to better and more durable outcomes and allowing patients to live longer and more meaningful lives.

Although accumulating data continue to show immunotherapy as a major step forward in the treatment of patients with non–small cell lung cancer (NSCLC), questions regarding optimal sequencing and treatment duration still remain. At the 17th Annual Winter Lung Cancer Conference®, hosted by Physicians’ Education Resource®, LLC, multiple presentations looked for answers to address these issues.

The case of a 64-year-old white woman with hepatitis C virus infection-related well-compensated cirrhosis with hepatocellular carcinoma recuurence.

Two case reports and a review of PCP in patients with solid tumors.